Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DEFENSE HEALTH AGENCY
Contract Value
Not provided
Codes & Classification
Solicitation Number
HT9402-26-Q-9403
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
The Department of Defense, through the Defense Health Agency (DHA), has issued a solicitation (Procurement Identifier: HT9402-26-Q-9403) seeking quotations from qualified pharmaceutical manufacturers for participation in the Department of War (DoW) Pharmacy Uniform Formulary Blanket Purchase Agreement (UF BPA) and the Uniform Formulary Additional Discount Program (UF ADP). This procurement is mandated by 10 U.S.C. § 1074g and its implementing regulation (32 CFR Section 199.21), which require the establishment of an effective, efficient, and integrated pharmacy benefits program for the Military Health System (MHS). The program’s primary objective is to ensure the availability of clinically effective and cost-efficient pharmaceutical agents to eligible beneficiaries.
The scope of this solicitation encompasses the provision of pharmaceutical agents within specific drug classes identified for potential placement on the DoW Uniform Formulary (UF). The Pharmacy and Therapeutics (P&T) Committee will evaluate the clinical and cost effectiveness of these agents, considering their inclusion as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF) options. The outcome of this process will inform the award of UF BPAs and UF ADP agreements, which are designed to secure favorable pricing and access for the MHS.
For the upcoming P&T Committee meeting in November 2026, the following newly approved drugs will be reviewed for potential formulary placement:
- Furoscix ReadyFlow (Diuretics)
- Gwyn Lo (Contraceptive Agents – Miscellaneous)
- Jideytro (Lung Cancer)
- Omlyclo (Atopy)
- RizaFilm (Migraine Agents)
- Zenbexus (Multiple Myeloma)
Interested offerors are required to review the attached Request for Quotation (RFQ), which includes detailed instructions, important deadlines, and appendices related to the UF BPA and UF ADP. A pre-quotation teleconference is scheduled for September 9, 2026, with participation details provided in Part 2.4 of the RFQ. Responses to clinical questions outlined in Part 3.4 must be submitted via email to the designated point of contact by the deadline specified in Part 2.3.2.
Key requirements for this opportunity include:
- Demonstrated capability in pharmaceutical preparation manufacturing, as classified under NAICS Code 325412 (Pharmaceutical Preparation Manufacturing, 2022).
- Submission of comprehensive quotations in accordance with the RFQ instructions.
- Timely response to clinical and administrative queries as outlined in the solicitation documents.
This procurement is not subject to any set-aside restrictions and is open to all qualified entities. The contracting activity is managed by the Defense Health Agency, a federal office under the Department of Defense. The primary point of contact for this solicitation is Stephanie Erpelding ([email protected]), with secondary support provided by Keith Marasigan (dha.san-antonio-tx.acquis-procure.mbx.pharmacy-support@health.mil).
The solicitation was posted on March 9, 2026, and remains active, with a response deadline of September 24, 2026, at 17:09. Interested parties are encouraged to review all nine attachments available via the official SAM.gov opportunity listing (https://sam.gov/opp/b1d938f1806c435896000816b83083d1/view) for complete details and submission requirements.
This opportunity represents a significant engagement for pharmaceutical manufacturers seeking to support the Military Health System’s pharmacy benefits program by providing clinically effective and cost-efficient medications to service members and their families.
Documents9